XNASCELZ
Market cap3mUSD
Dec 24, Last price
2.11USD
1D
-2.76%
1Q
-33.44%
IPO
18,247.83%
Name
Creative Medical Technology Holdings Inc
Chart & Performance
P/E
—
P/S
409.77
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
310.81%
Rev. gr., 5y
-40.86%
Revenues
9k
-89.84%
Net income
-5m
L-47.36%
CFO
-8m
L+2.96%
Earnings
Mar 20, 2025
Profile
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
IPO date
May 01, 2009
Employees
4
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | ||||||||||
Revenues | 9 -89.84% | 89 0.96% | 88 -46.65% | |||||||
Cost of revenue | 1,974 | 6,297 | 157 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,965) | (6,209) | (69) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (100) | 4,278 | ||||||||
Tax Rate | ||||||||||
NOPAT | (1,965) | (6,108) | (4,348) | |||||||
Net income | (5,287) -47.36% | (10,044) -167.26% | 14,933 -139.76% | |||||||
Dividends | (28) | |||||||||
Dividend yield | 3.86% | |||||||||
Proceeds from repurchase of equity | (271) | 15,472 | 14,562 | |||||||
BB yield | 4.18% | -3,713.64% | -2,028.26% | |||||||
| Debt | ||||||||||
Debt current | 14 | 14 | ||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 3,268 | |||||||||
Net debt | (9,987) | (18,385) | (10,710) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (8,028) | (7,797) | (2,216) | |||||||
CAPEX | ||||||||||
Cash from investing activities | 3,445 | (10,079) | ||||||||
Cash from financing activities | (271) | 15,472 | 12,842 | |||||||
FCF | (1,965) | (6,108) | (43,982) | |||||||
| Balance | ||||||||||
Cash | 9,987 | 18,399 | 10,724 | |||||||
Long term investments | ||||||||||
Excess cash | 9,987 | 18,395 | 10,719 | |||||||
Stockholders' equity | (59,097) | (53,798) | (43,661) | |||||||
Invested Capital | 69,441 | 69,677 | 53,893 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 1,408 | 1,093 | 325 | |||||||
Price | 4.61 1,109.66% | 0.38 -82.76% | 2.21 7,849.64% | |||||||
Market cap | 6,489 1,457.58% | 417 -41.97% | 718 44,467.84% | |||||||
EV | (3,498) | (17,968) | (9,992) | |||||||
EBITDA | (1,871) | (6,117) | 23 | |||||||
EV/EBITDA | 1.87 | 2.94 | ||||||||
Interest | 100 | 4,278 | ||||||||
Interest/NOPBT | ||||||||||